Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Mayne Pharma Group has received a formal notice of appeal from Cosette Pharmaceuticals and its BidCo lodged with the New South Wales Court of Appeal, challenging a prior Supreme Court judgment that had found in favour of Mayne Pharma. The appeal targets the court’s findings on Mayne Pharma’s FY25 EBITDA, which was central to Cosette’s misleading and deceptive conduct claim, and on Cosette’s allegation that a material adverse change had occurred based on Q3 FY25 sales metrics; Mayne Pharma has indicated it is reviewing the appeal and intends to vigorously defend the earlier ruling, signalling a continued legal overhang that could influence perceptions of the company’s financial performance and deal-related risk among investors and other stakeholders.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an ASX-listed specialty pharmaceutical company focused on commercialising novel medicines that improve safety, access and outcomes for patients. The company is a leader in dermatology and women’s health and also operates a global contract development and manufacturing business, leveraging four decades of expertise in advanced oral drug delivery technologies that underpin a range of products sold worldwide.
Average Trading Volume: 578,790
Technical Sentiment Signal: Sell
Current Market Cap: A$255.9M
See more data about MYX stock on TipRanks’ Stock Analysis page.